Journal of Inflammatory Bowel Diseases & Disorders

ISSN: 2476-1958

Open Access

Lim Vuanghao

Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, 13200 Kepala Batas, Penang, Malaysia

  • Short Communication   
    Role/Risks of Proton Pump Inhibitors and Infliximab in IBD Patients
    Author(s): Lim Vuanghao*

    Proton Pump Inhibitors (PPIs) are the most generally endorsed class of medicine for the treatment of indigestion and corrosive related issues. They work by obstructing the site of corrosive creation in the parietal cell of the stomach. Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases mainly Ulcerative Colitis (UC) and Crohn's Disease (CD). Infliximab targets TNF, thought to be more related to Th1 cytokines... Read More»
    DOI: 10.37421/2476-1958.2020.5.134

    Abstract HTML PDF

arrow_upward arrow_upward